메뉴 건너뛰기




Volumn 95, Issue 4, 2011, Pages 530-533

Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; RANIBIZUMAB;

EID: 79952992311     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.171868     Document Type: Article
Times cited : (34)

References (18)
  • 1
    • 0026681119 scopus 로고
    • Prevalence of age-related maculopathy: The Beaver Dam Eye Study
    • Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
    • (1992) Ophthalmology , vol.99 , pp. 933-943
    • Klein, R.1    Klein, B.E.2    Linton, K.L.3
  • 2
    • 0028839002 scopus 로고
    • The prevalence of age-related maculopathy in the Rotterdam study
    • Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 1995;102:205-10.
    • (1995) Ophthalmology , vol.102 , pp. 205-210
    • Vingerling, J.R.1    Dielemans, I.2    Hofman, A.3
  • 4
    • 77954720895 scopus 로고    scopus 로고
    • Technology appraisals TA 155, 2008 accessed 29 Jul 2010
    • National Institute for Clinical Excellence. Macular degeneration (age-related) - ranibizumab and pegaptanib. Technology appraisals TA 155, 2008. http://www.nice.org.uk/nicemedia/live/11700/40254/40254.pdf (accessed 29 Jul 2010).
    • Macular Degeneration (Age-related) - Ranibizumab and Pegaptanib
  • 5
    • 33749632278 scopus 로고    scopus 로고
    • Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
    • DOI 10.1097/01.iae.0000242842.14624.e7, PII 0000698220061000000002
    • Ferrara N, Damico L, Shams N, et al. Development of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. (Pubitemid 44547437)
    • (2006) Retina , vol.26 , Issue.8 , pp. 859-870
    • Ferrara, N.1    Damico, L.2    Shams, N.3    Lowman, H.4    Kim, R.5
  • 8
    • 33947403618 scopus 로고    scopus 로고
    • An OCT guided, variable dosing regimen with intravitreal Ranibizumab (Lucentis) for neovascular age-related macular degeneration
    • Fung AE, Lalwani GA, Rosenfeld PJ, et al. An OCT guided, variable dosing regimen with intravitreal Ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
    • (2007) Am J Ophthalmol , vol.143 , pp. 566-583
    • Fung, A.E.1    Lalwani, G.A.2    Rosenfeld, P.J.3
  • 9
    • 69249213449 scopus 로고    scopus 로고
    • Evaluation of injection frequency and visual acuity outcomes for Ranibizumab monotherapy in exudative age-related macular degeneration
    • Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for Ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-7.
    • (2009) Ophthalmology , vol.116 , pp. 1740-1747
    • Dadgostar, H.1    Ventura, A.A.2    Chung, J.Y.3
  • 10
    • 68949120732 scopus 로고    scopus 로고
    • Results of one-year's treatment with Ranibizumab for exudative age-related macular degeneration in a clinical setting
    • Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with Ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409-13.
    • (2009) Am J Ophthalmol , vol.148 , pp. 409-413
    • Cohen, S.Y.1    Dubois, L.2    Tadayoni, R.3
  • 11
    • 64649096877 scopus 로고    scopus 로고
    • Effects of Ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration
    • Rothenbuehler SP, Waeber D, Brinkman CK, et al. Effects of Ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009;147:831-7.
    • (2009) Am J Ophthalmol , vol.147 , pp. 831-837
    • Rothenbuehler, S.P.1    Waeber, D.2    Brinkman, C.K.3
  • 12
    • 69049121436 scopus 로고    scopus 로고
    • Ranibizumab treatment for neovascular age-related macular degeneration; from randomized trials to clinical practice
    • Michalova K, Wickremasinghe SS, Tan TH, et al. Ranibizumab treatment for neovascular age-related macular degeneration; from randomized trials to clinical practice. Eye 2009;23:1633-40.
    • (2009) Eye , vol.23 , pp. 1633-1640
    • Michalova, K.1    Wickremasinghe, S.S.2    Tan, T.H.3
  • 13
    • 79952984168 scopus 로고    scopus 로고
    • European Public Assessment Report (EPAR). accessed 6 Sep 2009
    • European Public Assessment Report (EPAR). Lucentis summary for the public: EMEA/H/C/715. http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H- 715-en1.pdf (accessed 6 Sep 2009).
    • Lucentis Summary for the Public: EMEA/H/C/715
  • 14
    • 32644470399 scopus 로고    scopus 로고
    • Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography
    • DOI 10.1001/archopht.124.2.193
    • Chan A, Duker J, Ko TH, et al. Normal macular thickness measurements in healthy eyes using stratus optical coherence tomography. Arch Ophthalmol 2006;124:193-8. (Pubitemid 43247068)
    • (2006) Archives of Ophthalmology , vol.124 , Issue.2 , pp. 193-198
    • Chan, A.1    Duker, J.S.2    Ko, T.H.3    Fujimoto, J.G.4    Schuman, J.S.5
  • 15
    • 34748844162 scopus 로고    scopus 로고
    • Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration
    • Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA Study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75.
    • (2007) Ophthalmology , vol.114 , pp. 1868-1875
    • Kaiser, P.K.1    Blodi, B.A.2    Shapiro, H.3
  • 16
    • 31644448419 scopus 로고    scopus 로고
    • Errors in retinal thickness measurements obtained by optical coherence tomography
    • DOI 10.1016/j.ophtha.2005.10.005, PII S0161642005011772
    • Sadda SR, Wu Z, Walsh AC, et al. Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006;113:285-93. (Pubitemid 43170778)
    • (2006) Ophthalmology , vol.113 , Issue.2 , pp. 285-293
    • Sadda, S.R.1    Wu, Z.2    Walsh, A.C.3    Richine, L.4    Dougall, J.5    Cortez, R.6    LaBree, L.D.7
  • 17
    • 14744274207 scopus 로고    scopus 로고
    • Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: A cross sectional study
    • DOI 10.1136/bjo.2004.043364
    • Sahni J, Stanga P, Wong D, et al. Optical coherence tomography in photodynamic therapy for subfoveal choroidal neovascularisation secondary to age related macular degeneration: a cross sectional study. Br J Ophthalmol 2005;89:316-20. (Pubitemid 40327616)
    • (2005) British Journal of Ophthalmology , vol.89 , Issue.3 , pp. 316-320
    • Sahni, J.1    Stanga, P.2    Wong, D.3    Harding, S.4
  • 18
    • 60149107965 scopus 로고    scopus 로고
    • Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss
    • Arias L, Armada F, Donate J, et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 2009;23:326-33.
    • (2009) Eye , vol.23 , pp. 326-333
    • Arias, L.1    Armada, F.2    Donate, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.